{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:37Z","timestamp":1790769337067,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":57,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_6","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:35:03Z","timestamp":1790764503000},"page":"103-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olezarsen for the Treatment of Hypertriglyceridemia"],"prefix":"10.1007","author":[{"given":"Antonio Sebastian Hernandez","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"11","key":"6_CR1","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.tips.2018.09.001","volume":"39","author":"D Li","year":"2018","unstructured":"Li D, Mastaglia FL, Fletcher S, Wilton SD (2018) Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends Pharmacol Sci 39(11):982\u2013994. https:\/\/doi.org\/10.1016\/j.tips.2018.09.001","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"6_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/00325481.2016.1243005","volume":"128","author":"PA Kushner","year":"2016","unstructured":"Kushner PA, Cobble ME (2016) Hypertriglyceridemia: the importance of identifying patients at risk. Postgrad Med 128(8):848\u2013858. https:\/\/doi.org\/10.1080\/00325481.2016.1243005","journal-title":"Postgrad Med"},{"issue":"3","key":"6_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","volume":"19","author":"RN Pejic","year":"2006","unstructured":"Pejic RN, Lee DT (2006) Hypertriglyceridemia.  J Am Board Family Med 19(3):310\u2013316. https:\/\/doi.org\/10.3122\/jabfm.19.3.310","journal-title":"J Am Board Family Med"},{"issue":"10","key":"6_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","volume":"25","author":"I Gouni-Berthold","year":"2023","unstructured":"Gouni-Berthold I, Schwarz J, Berthold HK (2023) Updates in drug treatment of severe hypertriglyceridemia. Curr Atheroscler Rep 25(10):701\u2013709. https:\/\/doi.org\/10.1007\/s11883-023-01140-z","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"6_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","volume":"21","author":"M-R Taskinen","year":"2019","unstructured":"Taskinen M-R, Packard CJ, Bor\u00e9n J (2019) Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep 21(8):27. https:\/\/doi.org\/10.1007\/s11883-019-0791-9","journal-title":"Curr Atheroscler Rep"},{"issue":"5-6","key":"6_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WF (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33(5-6):533\u2013540","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"6_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jimd.12251","volume":"44","author":"EC Kuijper","year":"2021","unstructured":"Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A (2021) Opportunities and challenges for antisense oligonucleotide therapies. J Inherit Metab Dis 44(1):72\u201387. https:\/\/doi.org\/10.1002\/jimd.12251","journal-title":"J Inherit Metab Dis"},{"key":"6_CR8","doi-asserted-by":"publisher","unstructured":"Sang A, Zhuo S, Bochanis A, Manautou JE, Bahal R, Zhong X-b et al (2024) Mechanisms of action of the US Food and Drug Administration-approved antisense oligonucleotide drugs. BioDrugs. https:\/\/doi.org\/10.1007\/s40259-024-00665-2.","DOI":"10.1007\/s40259-024-00665-2"},{"issue":"6","key":"6_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Baker BF, Crooke RM, Liang X-h (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20(6):427\u2013453. https:\/\/doi.org\/10.1038\/s41573-021-00162-z","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"6_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discovery 19(10):673\u2013694. https:\/\/doi.org\/10.1038\/s41573-020-0075-7","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"6_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnol 35(3):238\u2013248. https:\/\/doi.org\/10.1038\/nbt.3765","journal-title":"Nature Biotechnol"},{"issue":"4","key":"6_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40005-024-00669-8","volume":"54","author":"H Kim","year":"2024","unstructured":"Kim H, Kim S, Lee D, Lee D, Yoon J, Lee H (2024) Oligonucleotide therapeutics and their chemical modification strategies for clinical applications. J PharmaceutInvestig 54(4):415\u2013433. https:\/\/doi.org\/10.1007\/s40005-024-00669-8","journal-title":"J PharmaceutInvestig"},{"issue":"5","key":"6_CR13","doi-asserted-by":"publisher","first-page":"e1594","DOI":"10.1002\/wrna.1594","volume":"11","author":"AM Quemener","year":"2020","unstructured":"Quemener AM, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert M-D (2020) The powerful world of antisense oligonucleotides: from bench to bedside. WIREs RNA 11(5):e1594. https:\/\/doi.org\/10.1002\/wrna.1594","journal-title":"WIREs RNA"},{"issue":"6","key":"6_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch KM, Miller TM (2017) Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94(6):1056\u20131070. https:\/\/doi.org\/10.1016\/j.neuron.2017.04.010","journal-title":"Neuron"},{"issue":"11","key":"6_CR15","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","volume":"17","author":"M Shadid","year":"2021","unstructured":"Shadid M, Mohamed B, Abulrob A (2021) Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol 17(11):1281\u20131292. https:\/\/doi.org\/10.1080\/17425255.2021.1992382","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"6_CR16","doi-asserted-by":"publisher","first-page":"102440","DOI":"10.1016\/j.omtn.2024.102440","volume":"36","author":"S Naeem","year":"2025","unstructured":"Naeem S, Zhang J, Zhang Y, Wang Y (2025) Nucleic acid therapeutics: past, present, and future. Mol Ther Nucleic Acids 36(1):102440. https:\/\/doi.org\/10.1016\/j.omtn.2024.102440","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"6_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/nat.2023.0026","volume":"34","author":"BF Baker","year":"2024","unstructured":"Baker BF, Xia S, Partridge W, Engelhardt JA, Tsimikas S, Crooke ST et al. (2024) Safety and tolerability of GalNAc3-conjugated antisense drugs compared to the same-sequence 2\u2032-O-Methoxyethyl-modified antisense drugs: results from an integrated assessment of phase 1 clinical trial data. Nucleic Acid Ther 34(1):18\u201325. https:\/\/doi.org\/10.1089\/nat.2023.0026","journal-title":"Nucleic Acid Ther"},{"issue":"9","key":"6_CR18","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1210\/jc.2011-3213","volume":"97","author":"L Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH et al. (2012) Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97(9):2969\u20132989. https:\/\/doi.org\/10.1210\/jc.2011-3213","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M et al. (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.  Lancet Diabetes Endocrinol 2(8):655\u2013666. https:\/\/doi.org\/10.1016\/S2213-8587(13)70191-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","volume":"13","author":"JS Dron","year":"2019","unstructured":"Dron JS, Wang J, Cao H, McIntyre AD, Iacocca MA, Menard JR et al. (2019) Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol 13(1):80\u201388. https:\/\/doi.org\/10.1016\/j.jacl.2018.10.006","journal-title":"J Clin Lipidol"},{"issue":"6","key":"6_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.arteri.2020.04.001","volume":"32","author":"A Ruiz-Garc\u00eda","year":"2020","unstructured":"Ruiz-Garc\u00eda A, Arranz-Mart\u00ednez E, L\u00f3pez-Uriarte B, Rivera-Teijido M, Palacios-Mart\u00ednez D, D\u00e1vila-Bl\u00e1zquez GM et al. (2020) Prevalencia de hipertrigliceridemia en adultos y factores cardiometab\u00f3licos asociados. Estudio SIMETAP-HTG. Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis 32(6):242\u2013255. https:\/\/doi.org\/10.1016\/j.arteri.2020.04.001","journal-title":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"},{"issue":"1","key":"6_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jacl.2020.01.003","volume":"14","author":"JS Dron","year":"2020","unstructured":"Dron JS, Wang J, McIntyre AD, Cao H, Hegele RA (2020) The polygenic nature of mild-to-moderate hypertriglyceridemia. J Clin Lipidol 14(1):28\u201334.e2. https:\/\/doi.org\/10.1016\/j.jacl.2020.01.003","journal-title":"J Clin Lipidol"},{"issue":"1","key":"6_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA (2020) Clinical review on triglycerides. Eur Heart J 41(1):99\u2013109c","journal-title":"Eur Heart J"},{"issue":"1","key":"6_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12944-017-0625-0","volume":"16","author":"J Peng","year":"2017","unstructured":"Peng J, Luo F, Ruan G, Peng R, Li X (2017) Hypertriglyceridemia and atherosclerosis. Lipids Health Dis 16(1):233. https:\/\/doi.org\/10.1186\/s12944-017-0625-0","journal-title":"Lipids Health Dis"},{"issue":"8","key":"6_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1503\/cmaj.060963","volume":"176","author":"G Yuan","year":"2007","unstructured":"Yuan G, Al-Shali KZ, Hegele RA (2007) Hypertriglyceridemia: its etiology, effects and treatment. Can Med Assoc J 176(8):1113\u20131120. https:\/\/doi.org\/10.1503\/cmaj.060963","journal-title":"Can Med Assoc J"},{"issue":"6","key":"6_CR26","first-page":"347","volume":"102","author":"RC Oh","year":"2020","unstructured":"Oh RC, Trivette ET, Westerfield KL (2020) Management of hypertriglyceridemia: common questions and answers. Am Fam Physician 102(6):347\u2013354","journal-title":"Am Fam Physician"},{"issue":"8","key":"6_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11883-021-00939-y","volume":"23","author":"GD Carrasquilla","year":"2021","unstructured":"Carrasquilla GD, Christiansen MR, Kilpel\u00e4inen TO (2021) The genetic basis of hypertriglyceridemia. Curr Atheroscler Rep 23(8):39. https:\/\/doi.org\/10.1007\/s11883-021-00939-y","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"6_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","volume":"19","author":"F Javed","year":"2025","unstructured":"Javed F, Hegele RA, Garg A, Patni N, Gaudet D, Williams L et al. (2025) Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association. J Clin Lipidol 19(3):382\u2013403. https:\/\/doi.org\/10.1016\/j.jacl.2025.03.013","journal-title":"J Clin Lipidol"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fendo.2020.00455","volume":"11","author":"JS Dron","year":"2020","unstructured":"Dron JS, Hegele RA (2020) Genetics of hypertriglyceridemia. Front Endocrinol 11:455. https:\/\/doi.org\/10.3389\/fendo.2020.00455","journal-title":"Front Endocrinol"},{"issue":"12","key":"6_CR30","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1161\/ATVBAHA.122.318445","volume":"42","author":"MR Deshotels","year":"2022","unstructured":"Deshotels MR, Hadley TD, Roth M, Agha AM, Pulipati VP, Nugent AK et al. (2022) Genetic testing for hypertriglyceridemia in academic lipid clinics: implications for precision medicine\u2014brief report. Arterioscler Thromb Vasc Biol 42(12):1461\u20131467. https:\/\/doi.org\/10.1161\/ATVBAHA.122.318445","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"m3109","DOI":"10.1136\/bmj.m3109","volume":"371","author":"V Simha","year":"2020","unstructured":"Simha V (2020) Management of hypertriglyceridemia. BMJ 371:m3109. https:\/\/doi.org\/10.1136\/bmj.m3109","journal-title":"BMJ"},{"issue":"9","key":"6_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14656566.2023.2206015","volume":"24","author":"CM Spagnuolo","year":"2023","unstructured":"Spagnuolo CM, Hegele RA (2023) Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Expert Opin Pharmacother 24(9):1013\u20131020. https:\/\/doi.org\/10.1080\/14656566.2023.2206015","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"6_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/ph18020147","volume":"18","author":"JM Zimodro","year":"2025","unstructured":"Zimodro JM, Rizzo M, Gouni-Berthold I (2025) Current and emerging treatment options for hypertriglyceridemia: State-of-the-Art review. Pharmaceuticals 18(2):147. https:\/\/doi.org\/10.3390\/ph18020147","journal-title":"Pharmaceuticals"},{"issue":"5908","key":"6_CR34","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB et al. (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322(5908):1702\u20131705. https:\/\/doi.org\/10.1126\/science.1161524","journal-title":"Science"},{"key":"6_CR35","doi-asserted-by":"publisher","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen M-R (2020) The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. frontiers in endocrinology. 11. https:\/\/doi.org\/10.3389\/fendo.2020.00474","DOI":"10.3389\/fendo.2020.00474"},{"issue":"3","key":"6_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11883-023-01080-8","volume":"25","author":"A Giammanco","year":"2023","unstructured":"Giammanco A, Spina R, Cefal\u00f9 AB, Averna M (2023) APOC-III: a gatekeeper in controlling triglyceride metabolism. Curr Atheroscler Rep 25(3):67\u201376. https:\/\/doi.org\/10.1007\/s11883-023-01080-8","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"6_CR37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.4390","volume":"23","author":"SA Khetarpal","year":"2017","unstructured":"Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P et al. (2017) A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nature Med 23(9):1086\u20131094. https:\/\/doi.org\/10.1038\/nm.4390","journal-title":"Nature Med"},{"issue":"1","key":"6_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11883-025-01345-4","volume":"27","author":"S Tsimikas","year":"2025","unstructured":"Tsimikas S (2025) Anti-apoC-III therapies and implications for treatment of pancreatitis and cardiovascular disease. Curr Atheroscler Rep 27(1):103. https:\/\/doi.org\/10.1007\/s11883-025-01345-4","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"6_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12944-016-0286-4","volume":"15","author":"J Backes","year":"2016","unstructured":"Backes J, Anzalone D, Hilleman D, Catini J (2016) The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis 15(1):118. https:\/\/doi.org\/10.1186\/s12944-016-0286-4","journal-title":"Lipids Health Dis"},{"issue":"8","key":"6_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.tips.2025.05.007","volume":"46","author":"J Jin","year":"2025","unstructured":"Jin J, Nguyen LTG, Tawfik SM, Armanios B, Zhong X-B (2025) The ASO drug olezarsen targets familial chylomicronemia syndrome. Trends Pharmacol Sci 46(8):814\u2013815. https:\/\/doi.org\/10.1016\/j.tips.2025.05.007","journal-title":"Trends Pharmacol Sci"},{"key":"6_CR41","unstructured":"Tryngolza [Prescribing Information]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; 2024. Accessed December 10, 2025. https:\/\/ionis.com\/medicines\/TRYNGOLZA\/TRYNGOLZA-FPI.pdf"},{"key":"6_CR42","doi-asserted-by":"crossref","unstructured":"Syed YY (2025) Olezarsen: first approval. Drugs 85(4):571\u2013576. 10.1007\/s40265-025-02166-0","DOI":"10.1007\/s40265-025-02166-0"},{"key":"6_CR43","unstructured":"European Medicines Agency. Waylivra [Assessment report]. Amsterdam, Netherlands: European Medicines Agency; 2019. Accessed December 10, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/waylivra-epar-product-information_en.pdf"},{"key":"6_CR44","unstructured":"Faulknor J (2018) Safety, tolerability, PK, and pharmacodynamics (PD) of IONIS APOCIII-lrx in healthy volunteers with elevated triglycerides: ClinicalTrials.gov identifier: NCT02900027.\u2002https:\/\/clinicaltrials.gov\/study\/NCT02900027. Accessed 16 Nov 2025"},{"issue":"19","key":"6_CR45","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ES Stroes","year":"2024","unstructured":"Stroes ES, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM et al. (2024) Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med 390(19):1781\u20131792","journal-title":"N Engl J Med"},{"issue":"11","key":"6_CR46","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ et al. (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112(11):1479\u20131490. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.300367","journal-title":"Circ Res"},{"key":"6_CR47","unstructured":"FDA (2024) Ionis pharmaceuticals I. Application number: 218614Orig1s000."},{"issue":"11","key":"6_CR48","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.1097\/MS9.0000000000003768","volume":"87","author":"MS Khan","year":"2025","unstructured":"Khan MS, Chandani DK, Siddiqui E, Khalid M, Waafira A (2025) Olezarsen: FDA approval and clinical impact in familial chylomicronemia syndrome (FCS). Ann Med Surg 87(11):7846\u20137850","journal-title":"Ann Med Surg"},{"issue":"24","key":"6_CR49","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.3390\/molecules29245997","volume":"29","author":"R Allen","year":"2024","unstructured":"Allen R, Yokota T (2024) Endosomal escape and nuclear localization: critical barriers for therapeutic nucleic acids. Molecules 29(24):5997. https:\/\/doi.org\/10.3390\/molecules29245997","journal-title":"Molecules"},{"issue":"33","key":"6_CR50","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, Hughes SG, O\u2019Dea L, Geary RS et al. (2019) N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J 40(33):2785\u20132796. https:\/\/doi.org\/10.1093\/eurheartj\/ehz209","journal-title":"Eur Heart J"},{"issue":"14","key":"6_CR51","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"J-C Tardif","year":"2022","unstructured":"Tardif J-C, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM et al. (2022) Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 43(14):1401\u20131412. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820","journal-title":"Eur Heart J"},{"issue":"19","key":"6_CR52","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA et al. (2024) Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med 390(19):1770\u20131780. https:\/\/doi.org\/10.1056\/NEJMoa2402309","journal-title":"N Engl J Med"},{"issue":"13","key":"6_CR53","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA et al. (2025) Targeting APOC3 with olezarsen in moderate hypertriglyceridemia. N Engl J Med 393(13):1279\u20131291. https:\/\/doi.org\/10.1056\/NEJMoa2507227","journal-title":"N Engl J Med"},{"issue":"1","key":"6_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","volume":"23","author":"E Karwatowska-Prokopczuk","year":"2024","unstructured":"Karwatowska-Prokopczuk E, Lesogor A, Yan J-H, Hoenlinger A, Margolskee A, Li L et al. (2024) Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans. Lipids Health Dis 23(1):329. https:\/\/doi.org\/10.1186\/s12944-024-02297-5","journal-title":"Lipids Health Dis"},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa2512761","volume":"394","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bergmark BA, Alexander VJ et al. (2026) Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med 394:429\u2013441. https:\/\/doi.org\/10.1056\/NEJMoa2512761","journal-title":"N Engl J Med"},{"key":"6_CR56","unstructured":"Ionis Pharmaceuticals I (2025) CORE-OLE: a Study of Olezarsen (ISIS 678354) administered subcutaneously to participants with severe hypertriglyceridemia (SHTG) ClinicalTrials.gov identifier: NCT05681351. https:\/\/clinicaltrials.gov\/study\/NCT05681351. Accessed 16 Nov 2025"},{"key":"6_CR57","unstructured":"Ionis Pharmaceuticals I (2025) A study of olezarsen (formerly known as AKCEA-APOCIII-LRx) in participants with familial chylomicronemia syndrome (FCS): ClinicalTrials.gov identifier: NCT05130450. https:\/\/clinicaltrials.gov\/study\/NCT05130450. Accesed 16 Nov 2025"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:32Z","timestamp":1790766152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":57,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<b>Competing Interests<\/b>"}}]}}